Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Rentokil Initial plc

RTO
Industrials · Specialty Business Services

Rentokil Initial plc's earnings have outrun its stock. EPS grew +19.5% in a year against a +5.6% price move.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is building a base (3 weeks in). Underneath, the last four quarters read improving — profit +8.3% year on year, and 256% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.

Stage
Mixed
partial read
Price
$25.1
+5.6% 1Y
P/E
132.9×
of its own 4-year range
Revenue (Dec 25)
$3.5 B
+5.7% YoY
Profit (Dec 25)
$0.1 B
+8.3% YoY
Operating margin
7.9%
+0.1 pp YoY
ROE
6%
FY25
ROIC
7.4%
vs WACC 5.4% → +2.0 pp
Cash conversion
256%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Rentokil Initial plc trades at $25.1, building a base and 3 weeks into that stage. That is −17.3% against its own 200-day average. It sits at 16% of a 52-week range of $23 to $34. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (14 weeks and counting).

Today the stock is building a base — week 3 of stage 1. At $25.1 it trades −17.3% versus its 200-day average and sits at 16% of its 52-week range ($23–$34).

Aug 26: $25.1 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−17.3% versus the 200-day line, week 3 of stage 1
Price50-day avg200-day avg
S2S1S4S3S4S3S2$41.8$36.2$30.6$25.0$19.4$$25$30Jul 23Apr 24Jan 25Oct 25Aug 26
S2S1S4S3S4S3S2$41.8$36.2$30.6$25.0$19.4$$25$30Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +92% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (14 weeks and counting; last ahead the week of 2026-05-01) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Rentokil Initial plc trades at 132.9× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 132.9× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 132.9× vs a null× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 3.6-year window; loss-period spikes above 25× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
against too little history to rank
P/EEPS (TTM) (quarterly)
25.6×$1.922.0×$1.418.4×$0.914.8×$0.511.2×$0.0×$14.72×$2Jan 23Mar 24Jan 25Oct 25Aug 26
25.6×$1.922.0×$1.418.4×$0.914.8×$0.511.2×$0.0×$14.72×$2Jan 23Jan 25Aug 26
P/E
132.9×
too little history to rank
PEG
13.62
derived from 3-year earnings growth

Why the multiple sits where it does: over the past year annual EPS moved +19.5% against a +5.6% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the −13.2%/yr price move, ~+1.1%/yr came from earnings growth and ~−14.3 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Rentokil Initial plc reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE slipping at 11.1% — the per-curve reads carry the story. The read is built from 12 quarters across 3 curves, on partial evidence.

Growth, year by year: revenue +4.4% in FY25, profit −17.1% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
45%64%34%40%23%15%12%−8.8%0.7%−33%%%4.4%−17.1%FY21FY23FY25
45%64%34%40%23%15%12%−8.8%0.7%−33%%%4.4%−17.1%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over, profit rolling over
RevenueProfitEPS
63%331%49%219%34%108%20%0.0%6.3%−115%%%19.2%−15.8%4%Jun 20Dec 22Dec 25
63%331%49%219%34%108%20%0.0%6.3%−115%%%19.2%−15.8%4%Jun 20Dec 22Dec 25
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
25%21%18%14%10%%11.1%Jun 20Jun 21Dec 22Jun 24Dec 25
25%21%18%14%10%%11.1%Jun 20Dec 22Dec 25
Revenue growth
Rolling over
latest +19.2% · span +10.2% to +58.7%
Profit growth
Falling
latest −15.8% · span −83.9% to +300.0%
ROCE
Falling
latest 11.1% · span 11.1%–24.0%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+4.4%+15.5%
Profit−17.1%+1.2%
EPS+19.5%+9.8%
Stock price+5.6%−13.2%−8.7%+5.6%
Revenue YoY (Dec 25)
+5.7%
latest quarter vs a year ago
Profit YoY (Dec 25)
+8.3%
latest quarter vs a year ago
Revenue 10y
14.6%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

42.1/100 — rank 30 of 30 in Specialty Business Services · 43% evidence confidence · provisional, ranked below fully-evidenced peers

Rentokil Initial plc scores 42.1 out of 100 against the 30 companies it is compared with in Specialty Business Services, ranking 30. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 18.1 + 12.7 + 9.8 + 1.5 = 42.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Rentokil Initial plc reported $3.5 B of revenue in the Dec 25 quarter, +5.7% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at 14.6% a year. The last full year, FY25, came in at $6.9 B. The last four reported quarters add to $13.5 B.

FY25 revenue came in at $6.9 B (+4.4% on the year), capping 4 years at 14.6% compound. The latest quarter (Dec 25) printed $3.5 B, +5.7% year on year — the 2nd consecutive quarter of year-over-year growth.

FY25 revenue $6.9 B (+4.4% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
14.6% a year over 4 years
RevenueYoY growth
7.545%5.634%3.723%1.912%0.00.7%$ B%$7B4.4%FY21FY23FY25
7.545%5.634%3.723%1.912%0.00.7%$ B%$7B4.4%FY21FY23FY25
Dec 25: $3.5 B (+5.7% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
2nd straight quarter of growth
Revenue (quarterly)YoY growth
3.885%2.959%1.933%1.07.7%0.0−18%$ B%$4B5.7%Jun 20Dec 22Dec 25
3.885%2.959%1.933%1.07.7%0.0−18%$ B%$4B5.7%Jun 20Dec 22Dec 25

Pace check: the last four quarters averaged +0.4% growth against the decade's 14.6% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +19.2% over the last 4 quarters against +31.4%/yr over the last 8 — rolling over; TTM profit −15.8% vs +2.4%/yr — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Rentokil Initial plc's operating margin is 7.9% in the Dec 25 quarter, +0.1 percentage points against the same quarter a year ago. Across the last four quarters the operating margin has moved −3.9 percentage points. Across 5 fiscal years the operating margin has ranged 8.4% to 11.8%. The current quarter is running below every full year in that window.

The latest quarter's operating margin is 7.9%, +0.1 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 8.4%–11.8%.

🚨 Why the margin moved: operating margin went −3.9 pp year on year while gross margin went +0.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: 8.4% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 8.4–11.8% band over 5 years
operating marginYoY change (pp)
12%3.4%11%1.6%10%−0.2%9.1%−2.0%8.1%−3.8%%%8.4%−1.3%FY21FY23FY25
12%3.4%11%1.6%10%−0.2%9.1%−2.0%8.1%−3.8%%%8.4%−1.3%FY21FY23FY25
Dec 25: 7.9% operating margin (+0.1 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
13%5.6%11%2.6%9.8%−0.4%8.2%−3.4%6.6%−6.4%%%7.9%0.1%Jun 20Dec 22Dec 25
13%5.6%11%2.6%9.8%−0.4%8.2%−3.4%6.6%−6.4%%%7.9%0.1%Jun 20Dec 22Dec 25
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Rentokil Initial plc earned $0.1 B of net profit in the Dec 25 quarter, +8.3% year on year. Full-year FY25 profit was $0.3 B. The 4-year compound rate is −5.3%. That is 3.7% of the quarter's revenue. The same quarter a year earlier earned $0.3 B.

Dec 25 profit was $0.1 B, +8.3% year on year. On the full year, FY25 printed $0.3 B (−17.1%), and the 4-year compound rate is −5.3%.

FY25 profit $0.3 B (−17.1% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
−5.3% a year over 4 years
Net profitYoY growth
0.563%0.440%0.217%0.1−5.5%0.0−29%$ B%$0B−17.1%FY21FY23FY25
0.563%0.440%0.217%0.1−5.5%0.0−29%$ B%$0B−17.1%FY21FY23FY25
Dec 25: $0.1 B (+8.3% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.27184%0.20121%0.1457%0.07−6.1%0.00−69%$ B%$0B8.3%Jun 20Dec 22Dec 25
0.27184%0.20121%0.1457%0.07−6.1%0.00−69%$ B%$0B8.3%Jun 20Dec 22Dec 25

Why profit moved: revenue contributed +5.7% and the margin +0.1 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit −18.5% vs revenue +0.4%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 256% of Rentokil Initial plc's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.0 B of operating cash against $0.3 B of profit. After $0.2 B of capital spending, $0.8 B was left as free cash.

FY25: operating cash of $1.0 B against reported profit of $0.3 B, leaving free cash of $0.8 B after $0.2 B of capital spending. Across the last 3 fiscal years the conversion rate is 256% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $1.0 B vs profit $0.3 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
256% of 3-year profit arrived as cash
Operating cashNet profitFree cash
1.00.80.50.30.0$ B$1B$0B$1BFY21FY23FY25
1.00.80.50.30.0$ B$1B$0B$1BFY21FY23FY25
Jun 26: operating cash $0.4 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.5424%0.4337%0.3250%0.1163%0.076%$ B%$0B385%Dec 20Jun 23Jun 26
0.5424%0.4337%0.3250%0.1163%0.076%$ B%$0B385%Dec 20Jun 23Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Rentokil Initial plc does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 4.8% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $1.0 B over the last 3 fiscal years.

FY25: capex $0.2 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.240.180.120.060.00$ B$0BFY21FY23FY25
0.240.180.120.060.00$ B$0BFY21FY23FY25
Dec 24: capex $0.1 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)
0.120.090.060.030.00$ B$0BJun 19Dec 21Dec 24
0.120.090.060.030.00$ B$0BJun 19Dec 21Dec 24

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Rentokil Initial plc earns a ROE of 5% in FY25. Return on invested capital clears the cost of that capital by +2.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 4.2% net margin on 0.48× asset turns.

FY25 ROE is 5%.

Why the return is what it is — the wiring (FY25): 4.2% net margin × 0.48× asset turns × 2.63× balance-sheet leverage ≈ 5.3% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 7.4% − 5.4% = a +2.0 pp spread. The 5.4% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY25: ROE 5% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 5.4% cost of capital used on this page.
the full ladder
ROEROIC (annual)WACC
22%18%13%8.6%4.0%%5.3%5.3%FY21FY23FY25
22%18%13%8.6%4.0%%5.3%5.3%FY21FY23FY25
Jun 26: ROIC 4.2% (TTM) vs WACC 5.4% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
13%10%8.0%5.7%3.4%%4.2%6%Sep 23Dec 24Jun 26
13%10%8.0%5.7%3.4%%4.2%6%Sep 23Dec 24Jun 26
11 · Dividend

Dividend

Rentokil Initial plc pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Rentokil Initial plc does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Debt-to-equity is 1.11 at the latest reading — carrying real leverage; a full borrowings history is not in our numbers.

We hold only the latest reading here: a debt-to-equity of 1.11 — a level of leverage that amplifies both the returns above and the risk. A year-by-year borrowings ladder is not in our numbers for this stock, so we say that rather than draw a chart we cannot support.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

No ownership or positioning reading is held for Rentokil Initial plc, so this section names the gap rather than filling it. At typical trading volumes those positions would take about 3.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

We hold no ownership or positioning reading for this stock, so this section says that plainly.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Rentokil Initial plc: the Z-score reads 2.29. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 2.29 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 2.29.

15 · Related companies · Specialty Business Services
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1First Advantage CorporationFA 61.8/100Mixed-positive evidence64% evidence LEADER 24.6/35 Revenue 53.4% · PAT — · OPM change 6.6 pp 62% evidence 9.5/25 ROCE 0.9% · OPM 8.7% 76% evidence 8.5/20 P/E 294× · PEG — 15% evidence 19.2/20 RS sector 19.9% · RS bench 26% · 1Y 24.1%12 of 12 weeks ahead 100% evidence
Exact sum: 24.6 + 9.5 + 8.5 + 19.2 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2ABM Industries IncorporatedABM 60.4/100Mixed-positive evidence85% evidence BREAKING OUT 22.3/35 Revenue 6.5% · PAT 100% · OPM change -0.1 pp 95% evidence 11.4/25 ROCE 2.1% · OPM 3.8% 76% evidence 15.0/20 P/E 15.7× · PEG 0.38 65% evidence 11.7/20 RS sector -4.5% · RS bench 0.4% · 1Y 3%6 of 12 weeks ahead 100% evidence
Exact sum: 22.3 + 11.4 + 15 + 11.7 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3AramarkARMK 59.2/100Thin evidence · provisional58% evidence LEADER 20.0/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence 12.4/25 ROCE 2.1% · OPM 4.5% 76% evidence 9.7/20 P/E 32× · PEG — 15% evidence 17.1/20 RS sector 11% · RS bench 16.6% · 1Y 41.9%12 of 12 weeks ahead 100% evidence
Exact sum: 20 + 12.4 + 9.7 + 17.1 = 59.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Cintas CorporationCTAS 57.1/100Thin evidence · provisional58% evidence TURNING 20.2/35 Revenue — · PAT — · OPM change -0.2 pp 45% evidence 17.1/25 ROCE 8.4% · OPM 23.2% 76% evidence 9.6/20 P/E 34.9× · PEG — 15% evidence 10.2/20 RS sector -8.3% · RS bench -3.5% · 1Y -10%4 of 12 weeks ahead 100% evidence
Exact sum: 20.2 + 17.1 + 9.6 + 10.2 = 57.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5AZZ Inc.AZZ 55.2/100Mixed-positive evidence85% evidence ASLEEP 18.6/35 Revenue 5.7% · PAT -23.9% · OPM change 0.7 pp 95% evidence 13.8/25 ROCE 3.9% · OPM 17.2% 76% evidence 10.7/20 P/E 20.7× · PEG 1.43 65% evidence 12.1/20 RS sector 4.6% · RS bench 9.9% · 1Y 38.5%4 of 12 weeks ahead 100% evidence
Exact sum: 18.6 + 13.8 + 10.7 + 12.1 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Quad/Graphics, Inc.QUAD 54.7/100Thin evidence · provisional52% evidence BREAKING OUT 17.3/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence 9.3/25 ROCE 2.2% · OPM 3% 76% evidence 11.1/20 P/E 13.4× · PEG — 15% evidence 17.0/20 RS sector 31.4% · RS bench 37.8% · 1Y 69.3%5 of 12 weeks ahead 70% evidence
Exact sum: 17.3 + 9.3 + 11.1 + 17 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7CBIZ, Inc.CBZ 53.6/100Thin evidence · provisional58% evidence BREAKING OUT 14.3/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence 10.7/25 ROCE 0.8% · OPM 23.2% 76% evidence 10.9/20 P/E 15× · PEG — 15% evidence 17.7/20 RS sector 8.2% · RS bench 14% · 1Y -12.8%10 of 12 weeks ahead 100% evidence
Exact sum: 14.3 + 10.7 + 10.9 + 17.7 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Maximus, Inc.MMS 52.2/100Mixed-positive evidence81% evidence BASING 18.8/35 Revenue -1.5% · PAT 23.9% · OPM change 0.2 pp 83% evidence 14.3/25 ROCE 4.2% · OPM 11.4% 76% evidence 16.4/20 P/E 9.6× · PEG 0.29 65% evidence 2.7/20 RS sector -29.4% · RS bench -25.6% · 1Y -22.2%0 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 14.3 + 16.4 + 2.7 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Cimpress plcCMPR 51.2/100Thin evidence · provisional58% evidence LEADER 16.3/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence 11.2/25 ROCE 4.9% · OPM 5.5% 76% evidence 9.9/20 P/E 26.8× · PEG — 15% evidence 13.8/20 RS sector 14.3% · RS bench 20% · 1Y 85.6%11 of 12 weeks ahead 100% evidence
Exact sum: 16.3 + 11.2 + 9.9 + 13.8 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10Global Payments Inc.GPN 49.8/100Mixed-negative evidence81% evidence BREAKING OUT 12.9/35 Revenue 14.8% · PAT -55.2% · OPM change -20.9 pp 83% evidence 7.7/25 ROCE 0% · OPM -0.5% 76% evidence 15.6/20 P/E 13.4× · PEG 0.34 65% evidence 13.6/20 RS sector -2.2% · RS bench 3% · 1Y 9%5 of 12 weeks ahead 100% evidence
Exact sum: 12.9 + 7.7 + 15.6 + 13.6 = 49.8 · Decision use: Price leads the evidence: RS versus the benchmark is 3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
11RB Global, Inc.RBA 48.9/100Mixed-negative evidence81% evidence TURNING 21.1/35 Revenue 9.5% · PAT 7.3% · OPM change 0.5 pp 83% evidence 15.7/25 ROCE 7.5% · OPM 17.6% 76% evidence 4.3/20 P/E 44.1× · PEG 7.47 65% evidence 7.8/20 RS sector -11% · RS bench -6.4% · 1Y -2.7%1 of 12 weeks ahead 100% evidence
Exact sum: 21.1 + 15.7 + 4.3 + 7.8 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Cass Information Systems, Inc.CASS 48.9/100Thin evidence · provisional58% evidence BREAKING OUT 17.2/35 Revenue — · PAT — · OPM change -7.1 pp 45% evidence 4.4/25 ROCE -3.2% · OPM -37% 76% evidence 10.7/20 P/E 18.5× · PEG — 15% evidence 16.6/20 RS sector 8.5% · RS bench 14% · 1Y 38.3%4 of 12 weeks ahead 100% evidence
Exact sum: 17.2 + 4.4 + 10.7 + 16.6 = 48.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13UniFirst CorporationUNF 47.8/100Mixed-negative evidence85% evidence TURNING 10.7/35 Revenue 1.4% · PAT -24.3% · OPM change -4.3 pp 95% evidence 10.4/25 ROCE 0.9% · OPM 3.6% 76% evidence 11.3/20 P/E 41.9× · PEG 1.23 65% evidence 15.4/20 RS sector 13.1% · RS bench 18.6% · 1Y 68.7%4 of 12 weeks ahead 100% evidence
Exact sum: 10.7 + 10.4 + 11.3 + 15.4 = 47.8 · Decision use: Price leads the evidence: RS versus the benchmark is 18.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
14UL Solutions Inc.ULS 47.3/100Mixed-negative evidence81% evidence ASLEEP 23.7/35 Revenue 6.9% · PAT 4.2% · OPM change 2.7 pp 83% evidence 16.2/25 ROCE 6.7% · OPM 18.2% 76% evidence 4.9/20 P/E 50.1× · PEG 4 65% evidence 2.5/20 RS sector -18.4% · RS bench -14.2% · 1Y 17.6%3 of 12 weeks ahead 100% evidence
Exact sum: 23.7 + 16.2 + 4.9 + 2.5 = 47.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.4% and the one-year return is 17.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
15Thomson Reuters CorporationTRI 47.3/100Mixed-negative evidence81% evidence TURNING 18.9/35 Revenue 5.4% · PAT -25.9% · OPM change 1 pp 83% evidence 16.0/25 ROCE 4.3% · OPM 30.6% 76% evidence 5.5/20 P/E 26.6× · PEG 4.61 65% evidence 6.9/20 RS sector -22.7% · RS bench -18.5% · 1Y -40.3%1 of 12 weeks ahead 100% evidence
Exact sum: 18.9 + 16 + 5.5 + 6.9 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Dolby Laboratories, Inc.DLB 47.3/100Thin evidence · provisional58% evidence TURNING 16.6/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence 13.6/25 ROCE 1.2% · OPM 28.5% 76% evidence 10.2/20 P/E 22.8× · PEG — 15% evidence 6.9/20 RS sector -17.4% · RS bench -13% · 1Y -15.6%0 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 13.6 + 10.2 + 6.9 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Eastman Kodak CompanyKODK 47.3/100Thin evidence · provisional58% evidence ASLEEP 20.6/35 Revenue 4.4% · PAT -317.5% · OPM change 4.9 pp 62% evidence 6.8/25 ROCE -0.1% · OPM -0.4% 76% evidence 11.3/20 P/E 12.9× · PEG — 15% evidence 8.6/20 RS sector -7.4% · RS bench -2.8% · 1Y 26.8%4 of 12 weeks ahead 70% evidence
Exact sum: 20.6 + 6.8 + 11.3 + 8.6 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Transcat, Inc.TRNS 47.0/100Mixed-negative evidence75% evidence TURNING 12.8/35 Revenue 18.6% · PAT -61.5% · OPM change -4.2 pp 83% evidence 10.1/25 ROCE 1.1% · OPM 4.8% 76% evidence 9.7/20 P/E 125.1× · PEG 1.35 65% evidence 14.4/20 RS sector 6% · RS bench 11.4% · 1Y 16.1%8 of 12 weeks ahead 70% evidence
Exact sum: 12.8 + 10.1 + 9.7 + 14.4 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 11.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
19Copart, Inc.CPRT 41.4/100Mixed-negative evidence85% evidence BASING 16.8/35 Revenue 1.1% · PAT 5% · OPM change 0.2 pp 95% evidence 16.6/25 ROCE 5.2% · OPM 37.5% 76% evidence 6.6/20 P/E 20.6× · PEG 3.47 65% evidence 1.4/20 RS sector -33.8% · RS bench -30.3% · 1Y -36.3%0 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 16.6 + 6.6 + 1.4 = 41.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
20Amentum Holdings, Inc.AMTM 41.2/100Thin evidence · provisional58% evidence BASING 19.8/35 Revenue — · PAT — · OPM change 1.4 pp 45% evidence 9.0/25 ROCE 1.6% · OPM 4.3% 76% evidence 9.2/20 P/E 45.1× · PEG — 15% evidence 3.2/20 RS sector -21.2% · RS bench -17.1% · 1Y -3.9%0 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 9 + 9.2 + 3.2 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21Target Hospitality Corp.TH 37.9/100Mixed-negative evidence64% evidence FADING 9.3/35 Revenue -7.4% · PAT -197.8% · OPM change -18.2 pp 62% evidence 5.6/25 ROCE -2.9% · OPM -19.7% 76% evidence 9.0/20 P/E 71.2× · PEG — 15% evidence 14.0/20 RS sector 25.2% · RS bench 30.9% · 1Y 89.2%10 of 12 weeks ahead 100% evidence
Exact sum: 9.3 + 5.6 + 9 + 14 = 37.9 · Decision use: Price leads the evidence: RS versus the benchmark is 30.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
22LegalZoom.com, Inc.LZ 37.5/100Mixed-negative evidence75% evidence BREAKING OUT 10.3/35 Revenue 12.9% · PAT -60% · OPM change -3.6 pp 83% evidence 8.6/25 ROCE 1.5% · OPM 1.3% 76% evidence 12.0/20 P/E 94.5× · PEG 0.93 65% evidence 6.6/20 RS sector -13.7% · RS bench -9% · 1Y -23.5%6 of 12 weeks ahead 70% evidence
Exact sum: 10.3 + 8.6 + 12 + 6.6 = 37.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23BrightView Holdings, Inc.BV 35.3/100Mixed-negative evidence65% evidence ASLEEP 12.9/35 Revenue 0% · PAT 2.2% · OPM change -1.1 pp 83% evidence 7.5/25 ROCE 0.6% · OPM 2.3% 76% evidence 8.7/20 P/E 103.1× · PEG — 15% evidence 6.2/20 RS sector -14.2% · RS bench -9.8% · 1Y -13.6%6 of 12 weeks ahead 70% evidence
Exact sum: 12.9 + 7.5 + 8.7 + 6.2 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Resolute Holdings Management, Inc.RHLD 33.7/100Adverse evidence62% evidence TURNING 10.5/35 Revenue 82.2% · PAT -83.2% · OPM change -26 pp 83% evidence 7.3/25 ROCE -0.2% · OPM -1.4% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 5.9/20 RS sector -16.2% · RS bench -11.9% · 1Y 177.9%2 of 12 weeks ahead 70% evidence
Exact sum: 10.5 + 7.3 + 10 + 5.9 = 33.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25TIC Solutions, Inc.TIC 31.2/100Thin evidence · provisional53% evidence ASLEEP 14.9/35 Revenue — · PAT — · OPM change -2 pp 39% evidence 4.7/25 ROCE -1% · OPM -6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 1.6/20 RS sector -27.4% · RS bench -23.4% · 1Y -11.3%1 of 12 weeks ahead 100% evidence
Exact sum: 14.9 + 4.7 + 10 + 1.6 = 31.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26BlackSky Technology Inc.BKSY 29.7/100Thin evidence · provisional55% evidence ASLEEP 9.0/35 Revenue -9.3% · PAT — · OPM change -48.7 pp 62% evidence 3.8/25 ROCE -6.5% · OPM -89.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 6.9/20 RS sector -12.6% · RS bench -8.3% · 1Y 48.7%4 of 12 weeks ahead 70% evidence
Exact sum: 9 + 3.8 + 10 + 6.9 = 29.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Spire Global, Inc.SPIR 26.7/100Adverse evidence64% evidence ASLEEP 7.1/35 Revenue -36% · PAT — · OPM change -36.7 pp 62% evidence 3.1/25 ROCE -30.4% · OPM -155.2% 76% evidence 11.5/20 P/E 8.3× · PEG — 15% evidence 5.0/20 RS sector -8% · RS bench -3.6% · 1Y 40.4%6 of 12 weeks ahead 100% evidence
Exact sum: 7.1 + 3.1 + 11.5 + 5 = 26.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28RELX PLCRELX 52.3/100Thin evidence · provisional43% evidence TURNING 18.9/35 Revenue — · PAT — · OPM change — 12% evidence 16.1/25 ROCE 9.3% · OPM — 61% evidence 10.5/20 P/E 19.2× · PEG — 15% evidence 6.8/20 RS sector -18.5% · RS bench -14.2% · 1Y -23.3%1 of 12 weeks ahead 100% evidence
Exact sum: 18.9 + 16.1 + 10.5 + 6.8 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Public Policy Holding Company, Inc.PPHC 44.5/100Thin evidence · provisional11% evidence 17.5/35 Revenue — · PAT — · OPM change — 0% evidence 7.0/25 ROCE -11.5% · OPM — 46% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence
Exact sum: 17.5 + 7 + 10 + 10 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Rentokil Initial plcthis pageRTO 42.1/100Thin evidence · provisional43% evidence ASLEEP 18.1/35 Revenue — · PAT — · OPM change — 12% evidence 12.7/25 ROCE 1.8% · OPM — 61% evidence 9.8/20 P/E 30.3× · PEG — 15% evidence 1.5/20 RS sector -27% · RS bench -23.2% · 1Y -0.8%0 of 12 weeks ahead 100% evidence
Exact sum: 18.1 + 12.7 + 9.8 + 1.5 = 42.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Rentokil Initial plc's stock price today?

Rentokil Initial plc trades at $25.1, +5.6% over the past year. The company is valued at $13.0 B. The stock sits at 16% of its 52-week range of $23–$34, −17.3% versus its 200-day average. On the tape, the price is building a base, 3 weeks in. — as of 5 August 2026.

What were Rentokil Initial plc's latest quarterly results?

Rentokil Initial plc reported revenue of $3.5 B and net profit of $0.1 B for the Dec 25 quarter. Revenue rose 5.7% and profit rose 8.3% year on year. Earnings per share were $0.60. The operating margin was 7.9%, 0.1 pp higher than a year earlier. — as of 5 August 2026.

What is Rentokil Initial plc's revenue?

Rentokil Initial plc reported revenue of $3.5 B in the Dec 25 quarter, +5.7% year on year. For the full FY25 fiscal year, revenue was $6.9 B (+4.4%). Over the last 4 years revenue compounded at 14.6% a year. — as of 5 August 2026.

What is Rentokil Initial plc's profit?

Rentokil Initial plc earned $0.1 B of net profit in the Dec 25 quarter, +8.3% year on year. Full-year FY25 profit was $0.3 B. The operating margin ran 7.9% in the latest quarter. — as of 5 August 2026.

What is Rentokil Initial plc's market cap?

Rentokil Initial plc's market capitalisation is $13.0 B at a stock price of $25.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

Does Rentokil Initial plc pay a dividend?

No — Rentokil Initial plc has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

Is Rentokil Initial plc growing?

Yes — Rentokil Initial plc is growing: latest-quarter revenue +5.7% year on year, profit +8.3%, and the margin +0.1 pp at 7.9%. The 4-year compound rates are 14.6% (revenue) and −5.3% (profit). The earnings engine currently reads: improving — as of 5 August 2026.

How is Rentokil Initial plc performing?

Rentokil Initial plc is building a base, 3 weeks in. Its latest quarter's revenue rose 5.7% and profit rose 8.3% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Rentokil Initial plc in?

Mixed — no clean majority across the growth curves, ROCE slipping at 11.1% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +19.2% latest, profit growth −15.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Rentokil Initial plc in an uptrend?

No — the price is building a base (week 3 of stage 1), trading −17.3% versus its 200-day average and at 16% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Rentokil Initial plc beating the market?

Not lately — on a trailing-13-week view Rentokil Initial plc is currently behind the S&P 500 (14 weeks and counting; last ahead the week of 2026-05-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +92% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.

Will Rentokil Initial plc's stock price go up?

This page publishes no price forecast for Rentokil Initial plc. What it measures instead: the stock price is $25.1, the price is building a base 3 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.

Does Rentokil Initial plc have too much debt?

It carries real leverage — Rentokil Initial plc's debt-to-equity is 1.11. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.

What is Rentokil Initial plc's capex?

Rentokil Initial plc spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.2 B. — as of 5 August 2026.

What is Rentokil Initial plc's cash flow?

Rentokil Initial plc generated $1.0 B of operating cash flow in FY25 and $0.8 B of free cash flow after $0.2 B of capital spending. Reported profit that year was $0.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is Rentokil Initial plc's profit real cash?

Yes — over the last 3 fiscal years, 256% of Rentokil Initial plc's reported profit arrived as operating cash. In FY25, operating cash was $1.0 B against reported profit of $0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is Rentokil Initial plc?

On the balance sheet, the Z-score reads 2.29 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.

Where is Rentokil Initial plc in its business cycle?

Rentokil Initial plc's FY25 operating margin was 8.4%, against a 5-year band of 8.4%–11.8%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 7.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Rentokil Initial plc story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Rentokil Initial plc a stock worth studying right now?

This is not investment advice. The machine read: Rentokil Initial plc's earnings have outrun its stock. EPS grew +19.5% in a year against a +5.6% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI